Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
- 329 Downloads
This study assessed the safety, immunogenicity, and pharmacokinetics of etaracizumab, a monoclonal antibody directed against the αvβ3 integrin, in patients with advanced malignancies. Four cohorts of four patients received escalating dose of etaracizumab as a 30-min intravenous infusion, first as a single test dose, followed-up 2–5 weeks later by weekly doses. Sixteen patients with advanced solid tumors received a total of 309 cycles of etaracizumab at doses ranging 1–6 mg/kg. The mean number of weekly infusions was 19 (ranging 5–53). Frequently reported adverse events were grades 1–2 asthenia (15 patients) and infusion reactions (9 patients). At 1 mg/kg, one patient experienced grade 3 chills with the first infusion. Other grade 3 toxicities included reversible hyponatremia, hypophosphatemia and hyponatremia in one patient each at 1, 4 and 6 mg/kg, respectively. No patient experienced treatment delay/discontinuation due to an adverse event. The half-life of etaracizumab ranged 49–180 h with a nonlinear increase in terminal half-life with increasing doses. There was no objective response but five patients experienced a stable disease of >6-month duration. Etaracizumab was well-tolerated at doses up to 6 mg/kg with no evidence of immunogenicity. The safety profile of etaracizumab warrants further exploration in ongoing phase I/II trials.
KeywordsAngiogenesis αvβ3 receptor Advanced solid tumors Endothelial cell adhesion Vitaxin MEDI-522
Dr. Delbaldo was supported by a grant from the “Ligue Genevoise contre le Cancer”.
- 32.World Health Organization (1979) WHO handbook for reporting results of cancer treatment (offset publication 48). World Health Organization, Geneva, SwitzerlandGoogle Scholar
- 36.Gray R, Giantonio BJ, O’Dwyer PJ et al (2003) The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group’s (ECOG) experience with bevacizumab (anti-VEGF). Proc Am Soc Clin Oncol 22:206 (Abstract 825)Google Scholar
- 37.Benson AB, Catalano PJ, Meropol NJ et al (2003) Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 22:243 (Abstract 975)Google Scholar
- 40.Hersey P, Sosman S, O’Day J, Richards A, Bedikian R, Gonzalez W et al (2005) A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alphavbeta3 integrin+dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 24 (Abstract 7507)Google Scholar